Loading page
Loading page
Loading substance route
Exceptionally potent. Life-threatening adverse reactions documented at 3 mg.
Effects vary widely by individual, dose, and context.
The physical effects of flubromazolam can be broken down into several components which progressively intensify proportional to dosage.
The cognitive effects of flubromazolam can be broken down into several components which progressively intensify proportional to dosage. The general head space of flubromazolam is described by many as one of intense sedation and decreased inhibition. It contains a large number of typical depressant cognitive effects.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Flubromazolam is described as extremely psychologically addictive. Compulsive redosing is commonly reported, and cycles of dependence can readily develop from rebound anxiety that follows the substance's effects wearing off.
Physical dependence develops with regular use and can become life-threatening. Abrupt discontinuation after weeks of steady dosing can result in hypertension, seizures, and death. Gradual tapering over a prolonged period is essential for safe discontinuation.
Flubromazolam has relatively low toxicity when used alone. However, life-threatening adverse reactions have been observed at doses as low as 3 mg. Fatal overdose is significantly more likely when combined with other CNS depressants such as alcohol, opioids, or barbiturates, which potentiate respiratory depression.
Respiratory depression occurs as a direct pharmacological effect with severity proportional to dose; this becomes potentially fatal when combined with other CNS depressants but rarely causes death from flubromazolam alone at typical doses.
Paradoxical reactions including aggression, violent behavior, loss of impulse control, and irritability occur rarely, with an incidence rate below 1% in the general population. Delusions of sobriety commonly occur at heavy doses but represent cognitive impairment rather than true psychosis. Paradoxical effects are more frequent in recreational abusers, individuals with mental disorders, children, and those on high-dosage regimes.
Benzodiazepines possess anticonvulsant properties during active use. Paradoxical seizure increases are rare and primarily affect individuals with epilepsy. However, withdrawal from regular use poses significant seizure risk that can be fatal; drugs that lower seizure threshold should be avoided during discontinuation, and gradual tapering is essential.
Flubromazolam, also designated JYI-73, is a novel synthetic triazolobenzodiazepine that emerged as part of the broader wave of designer benzodiazepines appearing on recreational drug markets. The substance first came to the attention of drug monitoring agencies following seizures by customs and law…
All benzodiazepines are controlled under Schedule IV of the Controlled Drugs and Substances Act.
Controlled under List 2 of the Opium Law (Opiumwet), making possession, distribution, and production illegal.
Listed as a Schedule III controlled substance since 2017 under Russian narcotics legislation.
Classified as a controlled drug under Turkish law. Possession, production, supply, and import are all prohibited.
Placed into Schedule I of the Controlled Substances Act as of January 23, 2023, indicating classification as having high abuse potential with no currently accepted medical use.
Controlled under the New Psychoactive Substances Act since July 18, 2019. Production and import with intent to distribute, administration to another person, and trading are punishable offenses. Possession is technically illegal but not subject to criminal penalties.
Classified as a New Psychoactive Substance (NPS) under Polish drug legislation, making both possession and distribution illegal.
Specifically named as a controlled substance under Verzeichnis E of the Swiss Narcotics Act (Betäubungsmittelgesetz).
Designated as a Class C controlled substance under the Misuse of Drugs Act 1971 as of May 31, 2017. Possession, production, and supply carry criminal penalties.
16 sources cited
